By Fineline Cube Suzhou Ribo Life Science Co., Ltd. (HKG: 6938) announced it has submitted a Phase II clinical trial application to the European Medicines Agency (EMA) for RBD1119, a small interfering RNA (siRNA) drug developed for the treatment of coronary artery disease (CAD).
Regulatory Filing Details
| Item | Detail |
|---|---|
| Agency | EMA (European Union) |
| Filing Type | Phase II Clinical Trial Application |
| Product | RBD1119 (siRNA therapeutic) |
| Indication | Treatment of coronary artery disease |
| Filing Date | 29 May 2026 |
| Next Steps | EMA review period; potential approval for Phase II initiation within 60-90 days |
Drug Profile & Mechanism of Action
- Molecule: Small interfering RNA (siRNA) antithrombotic therapeutic
- Platform: Developed using Ribo Life Sciences’ proprietary RiboGalSTAR siRNA platform
- Target: Thrombosis-related factors involved in CAD progression
- Innovation: Provides effective and durable thromboprophylaxis while maintaining a favorable safety profile, particularly regarding bleeding risk
- Differentiation: Addresses limitations of current antiplatelet and anticoagulant therapies that inadequately control thrombotic events
Clinical & Market Context
| Aspect | Current Standard of Care | RBD1119 Potential Advantage |
|---|---|---|
| Therapeutic Approach | Antiplatelet/anticoagulant drugs | Targeted siRNA therapy |
| Efficacy | Inadequate control of thrombotic events | Potentially superior thromboprophylaxis |
| Safety Profile | Significant bleeding risk | Favorable safety profile with reduced bleeding risk |
| Durability | Requires continuous dosing | Potential for extended effect due to siRNA mechanism |
Coronary artery disease remains a leading cause of morbidity and mortality among cardiovascular patients worldwide, creating substantial unmet medical need.
Market Impact & Strategic Outlook
- European CAD Market: Estimated at €8.2 billion annually, with limited innovation in antithrombotic therapies over the past decade
- Competitive Landscape: RBD1119 would be among the first siRNA-based antithrombotics to reach European markets if approved
- Global Strategy: EMA filing represents a key milestone in Ribo Life Science’s international expansion beyond its Chinese base
- Investment Implications: Successful Phase II results could significantly enhance the company’s valuation and attract partnership interest from major cardiovascular-focused pharmaceutical companies
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory filings, clinical development, and commercial potential for RBD1119. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, and competitive dynamics.-Fineline Info & Tech